source
- Biogen’s experimental Alzheimer’s therapy shows comparable slowing of cognitive decline in mid-stage trial, paving way to Phase 3Biogen reported that its experimental Alzheimer’s drug slowed cognitive decline in a mid-stage study. The trial showed patients experienced a rate of decline similar to that seen with currently app…
- Nava Therapeutics raises $89 million to advance lipid nanoparticle platform targeting bone marrow, immune cells and kidneyNava Therapeutics, a stealth-mode biotech, announced it has secured $89 million in financing, according to a statement to Endpoints News. The capital will support development of a next generation…Endpoints · 1mo agoDealPositive